Viridian Therapeutics Q3 Net Loss Widens, Revenue Drops

09:08 AM EST, 11/04/2026 (MT Newswires) -- Viridian Therapeutics (VRDN) reported a Q3 net loss Wednesday of $0.81 per diluted share, wider than a loss of $0.34 a year earlier. Analysts polled by FactSet expected a loss of $1.00. Revenue for the quarter ended Sept. 30 was $25.8 million, down from $70.6 million a year earlier. As of Sept. 30, the company said it had $955.2 million in cash, cash equivalents and marketable securities. The company's shares were up 9.3% in premarket activity Wednesday.